ES2412273T3
(es)
|
2002-11-21 |
2013-07-10 |
Novartis Ag |
Inhibidores de 2-morfolín-4-pirimidinas como inhibidores de fosfotidilinositol (PI) 3-quinasa y su uso en el tratamiento del cáncer.
|
US20050014753A1
(en)
*
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
AU2004275720B2
(en)
*
|
2003-09-23 |
2008-04-24 |
Merck Sharp & Dohme Corp. |
Isoquinoline potassium channel inhibitors
|
EP1885352A2
(en)
*
|
2004-11-24 |
2008-02-13 |
Novartis AG |
Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
|
AU2006218020A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Novartis Ag |
Pharmaceutical combination of Bcr-Abl and RAF inhibitors
|
JP5079500B2
(ja)
*
|
2005-04-28 |
2012-11-21 |
協和発酵キリン株式会社 |
2−アミノキナゾリン誘導体
|
BRPI0608604B8
(pt)
|
2005-05-10 |
2021-05-25 |
Incyte Corp |
moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
|
CA2621261C
(en)
|
2005-09-22 |
2014-05-20 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
WO2007056625A2
(en)
*
|
2005-11-04 |
2007-05-18 |
Smithkline Beecham Corporation |
Thienopyridine b-raf kinase inhibitors
|
DK2343299T3
(en)
|
2005-12-13 |
2016-01-18 |
Incyte Holdings Corp |
Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
|
JO2660B1
(en)
*
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
DE102006012544A1
(de)
*
|
2006-03-18 |
2007-09-27 |
Sanofi-Aventis |
Substituierte 1-Amino 4-phenyl-dihydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
|
US20090098137A1
(en)
|
2006-04-05 |
2009-04-16 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
FR2903107B1
(fr)
|
2006-07-03 |
2008-08-22 |
Sanofi Aventis Sa |
Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
|
FR2903105A1
(fr)
|
2006-07-03 |
2008-01-04 |
Sanofi Aventis Sa |
Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
|
WO2008009078A2
(en)
|
2006-07-20 |
2008-01-24 |
Gilead Sciences, Inc. |
4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
|
WO2008009077A2
(en)
*
|
2006-07-20 |
2008-01-24 |
Gilead Sciences, Inc. |
4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
|
EP2069325A2
(en)
*
|
2006-08-24 |
2009-06-17 |
Serenex, Inc. |
Isoquinoline, quinazoline and phthalazine derivatives
|
ES2415863T3
(es)
|
2006-12-22 |
2013-07-29 |
Incyte Corporation |
Heterociclos sustituidos como inhibidores de Janus Quinasas
|
US8173647B2
(en)
|
2007-02-06 |
2012-05-08 |
Gordana Atallah |
PI 3-kinase inhibitors and methods of their use
|
ES2575797T3
(es)
|
2007-06-13 |
2016-07-01 |
Incyte Holdings Corporation |
Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
EP2220068B1
(en)
|
2007-11-16 |
2016-01-27 |
Incyte Holdings Corporation |
4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
PT2288610T
(pt)
|
2008-03-11 |
2016-10-17 |
Incyte Holdings Corp |
Derivados de azetidina e de ciclobutano como inibidores de jak
|
WO2009132202A2
(en)
|
2008-04-24 |
2009-10-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
AR072297A1
(es)
|
2008-06-27 |
2010-08-18 |
Novartis Ag |
Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
|
PE20110308A1
(es)
|
2008-07-08 |
2011-06-10 |
Incyte Corp |
1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
|
GB0812969D0
(en)
|
2008-07-15 |
2008-08-20 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
KR20100032496A
(ko)
*
|
2008-09-18 |
2010-03-26 |
주식회사 이큐스팜 |
신규 5-(4-아미노페닐)-이소퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 치료용 조성물
|
CL2009001884A1
(es)
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
GB2465405A
(en)
*
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
CA2748607A1
(en)
*
|
2008-12-31 |
2010-07-08 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
WO2010085597A1
(en)
|
2009-01-23 |
2010-07-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
DK2432472T3
(da)
|
2009-05-22 |
2019-11-18 |
Incyte Holdings Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
|
EP2432555B1
(en)
|
2009-05-22 |
2014-04-30 |
Incyte Corporation |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
CN104945420A
(zh)
|
2009-06-29 |
2015-09-30 |
因塞特公司 |
作为pi3k抑制剂的嘧啶酮类
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
CA2777114C
(en)
|
2009-10-09 |
2018-10-23 |
Incyte Corporation |
Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
US8680108B2
(en)
|
2009-12-18 |
2014-03-25 |
Incyte Corporation |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
MX2012009541A
(es)
|
2010-02-18 |
2012-10-01 |
Incyte Corp |
Derivados de ciclobutano y metilciclobutano como inhibidores de janus cinasa.
|
MX364636B
(es)
|
2010-03-10 |
2019-05-03 |
Incyte Corp |
Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
|
WO2011130342A1
(en)
|
2010-04-14 |
2011-10-20 |
Incyte Corporation |
FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
|
EP3087972A1
(en)
|
2010-05-21 |
2016-11-02 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
AU2011329734B2
(en)
|
2010-11-19 |
2015-05-28 |
Incyte Holdings Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
JP5917544B2
(ja)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
|
WO2012087881A1
(en)
|
2010-12-20 |
2012-06-28 |
Incyte Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
BR112013020798B1
(pt)
|
2011-02-18 |
2022-03-15 |
Incyte Corporation |
Uso e composição contendo uma combinação de um inibidor mtor e de um inibidor de jak para tratamento de neoplasisas mieloproliferativas
|
US9108984B2
(en)
|
2011-03-14 |
2015-08-18 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
KR20140040819A
(ko)
|
2011-06-20 |
2014-04-03 |
인사이트 코포레이션 |
Jak 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
|
CA2844507A1
(en)
|
2011-08-10 |
2013-02-14 |
Novartis Pharma Ag |
Jak pi3k/mtor combination therapy
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
PE20181272A1
(es)
|
2011-09-02 |
2018-08-03 |
Incyte Holdings Corp |
Heterociclilaminas como inhibidores de pi3k
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
EA025183B1
(ru)
|
2011-09-27 |
2016-11-30 |
Новартис Аг |
3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh
|
JP6363020B2
(ja)
|
2012-01-30 |
2018-07-25 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
イソキノリンおよびナフチリジン誘導体
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
IL289834B1
(en)
|
2012-06-13 |
2024-03-01 |
Incyte Holdings Corp |
Conversion of tricyclic compounds as FGFR inhibitors
|
CN102702109B
(zh)
*
|
2012-06-15 |
2014-07-23 |
华东理工大学 |
苯磺酰胺类化合物及其用途
|
US20150133450A1
(en)
|
2012-06-20 |
2015-05-14 |
Eutropics Pharmaceuticals, Inc. |
Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
|
WO2014041349A1
(en)
*
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
RU2015113597A
(ru)
*
|
2012-09-14 |
2016-11-10 |
Итернити Байосайенс Инк. |
Производные аминоизохинолина в качестве ингибиторов протеинкиназы
|
SG10201703533VA
(en)
|
2012-11-01 |
2017-06-29 |
Incyte Corp |
Tricyclic fused thiophene derivatives as jak inhibitors
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
EP3949953A1
(en)
|
2012-11-15 |
2022-02-09 |
Incyte Holdings Corporation |
Sustained-release dosage forms of ruxolitinib
|
US20160038503A1
(en)
*
|
2012-11-21 |
2016-02-11 |
David Richard |
Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
|
TW202333734A
(zh)
|
2013-03-01 |
2023-09-01 |
美商英塞特控股公司 |
吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
|
EP3489239B1
(en)
|
2013-03-06 |
2021-09-15 |
Incyte Holdings Corporation |
Processes and intermediates for making a jak inhibitor
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
MX355945B
(es)
|
2013-03-14 |
2018-05-07 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
|
SG10201708520YA
(en)
|
2013-04-19 |
2017-12-28 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
FI3786162T3
(fi)
|
2013-05-17 |
2023-10-02 |
Incyte Holdings Corp |
Bipyratsolijohdannaisia jak-inhibiittoreina
|
US10732182B2
(en)
|
2013-08-01 |
2020-08-04 |
Eutropics Pharmaceuticals, Inc. |
Method for predicting cancer sensitivity
|
PT3030227T
(pt)
|
2013-08-07 |
2020-06-25 |
Incyte Corp |
Formas de dosagem de libertação prolongada para um inibidor de jak1
|
CA2921568A1
(en)
|
2013-08-20 |
2015-02-25 |
Incyte Corporation |
Survival benefit in patients with solid tumors with elevated c-reactive protein levels
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
WO2015041533A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
Rock in combination with mapk-pathway
|
US10640803B2
(en)
|
2013-10-30 |
2020-05-05 |
Eutropics Pharmaceuticals, Inc. |
Methods for determining chemosensitivity and chemotoxicity
|
SG11201607083VA
(en)
|
2014-02-28 |
2016-09-29 |
Incyte Corp |
Jak1 inhibitors for the treatment of myelodysplastic syndromes
|
EP2929883A1
(en)
|
2014-04-08 |
2015-10-14 |
Institut Pasteur |
Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
|
EP3795152A1
(en)
|
2014-04-08 |
2021-03-24 |
Incyte Corporation |
Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
CA2947418A1
(en)
|
2014-04-30 |
2015-11-05 |
Incyte Corporation |
Processes of preparing a jak1 inhibitor and new forms thereto
|
WO2015178770A1
(en)
|
2014-05-19 |
2015-11-26 |
Stichting Het Nederlands Kanker Instituut |
Compositions for cancer treatment
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
US11920164B2
(en)
|
2014-07-30 |
2024-03-05 |
Yeda Research And Development Co. Ltd. |
Media for culturing naive human pluripotent stem cells
|
CN107074828B
(zh)
*
|
2014-09-12 |
2020-05-19 |
诺华股份有限公司 |
用作raf激酶抑制剂的化合物和组合物
|
WO2016050201A1
(zh)
*
|
2014-09-29 |
2016-04-07 |
山东轩竹医药科技有限公司 |
高选择性取代嘧啶类pi3k抑制剂
|
US9586949B2
(en)
|
2015-02-09 |
2017-03-07 |
Incyte Corporation |
Aza-heteroaryl compounds as PI3K-gamma inhibitors
|
KR20170117479A
(ko)
|
2015-02-11 |
2017-10-23 |
바실리어 파마슈티카 인터내셔널 리미티드 |
치환된 모노- 및 폴리아자나프탈렌 유도체 및 이의 용도
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
MX2017010673A
(es)
|
2015-02-20 |
2018-03-21 |
Incyte Corp |
Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
|
RS63963B1
(sr)
|
2015-02-27 |
2023-03-31 |
Incyte Holdings Corp |
Postupak pripreme pi3k inhibitora
|
PT3097102T
(pt)
|
2015-03-04 |
2018-01-22 |
Gilead Sciences Inc |
Compostos de 4,6-diamino-pirido[3,2-d]pirimidina que modulam recetor do tipo toll
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
US9732097B2
(en)
|
2015-05-11 |
2017-08-15 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
US20160362424A1
(en)
|
2015-05-11 |
2016-12-15 |
Incyte Corporation |
Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
|
WO2017079519A1
(en)
|
2015-11-06 |
2017-05-11 |
Incyte Corporation |
Heterocyclic compounds as pi3k-gamma inhibitors
|
MA54567A
(fr)
|
2016-01-05 |
2021-10-27 |
Incyte Corp |
Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
|
WO2017223414A1
(en)
|
2016-06-24 |
2017-12-28 |
Incyte Corporation |
HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
AU2017318601B2
(en)
|
2016-09-02 |
2020-09-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
CA3047700A1
(en)
*
|
2016-12-28 |
2018-07-05 |
Minoryx Therapeutics S.L. |
Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
CR20200214A
(es)
|
2017-10-18 |
2020-07-25 |
Incyte Corp |
ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
WO2019126505A1
(en)
|
2017-12-21 |
2019-06-27 |
Incyte Corporation |
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
|
AR114810A1
(es)
|
2018-01-30 |
2020-10-21 |
Incyte Corp |
Procesos e intermedios para elaborar un inhibidor de jak
|
SG11202007805SA
(en)
|
2018-02-16 |
2020-09-29 |
Incyte Corp |
Jak1 pathway inhibitors for the treatment of cytokine-related disorders
|
CN112384515A
(zh)
|
2018-02-27 |
2021-02-19 |
因赛特公司 |
作为a2a/a2b抑制剂的咪唑并嘧啶和***并嘧啶
|
TWI827583B
(zh)
|
2018-03-08 |
2024-01-01 |
美商英塞特公司 |
作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
|
MX2022012285A
(es)
|
2018-03-30 |
2023-08-15 |
Incyte Corp |
Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
US11174257B2
(en)
|
2018-05-04 |
2021-11-16 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
MX2020012376A
(es)
|
2018-05-18 |
2021-03-09 |
Incyte Corp |
Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
|
EP3802534B1
(en)
|
2018-05-25 |
2022-07-13 |
Incyte Corporation |
Tricyclic heterocyclic compounds as sting activators
|
US11046658B2
(en)
|
2018-07-02 |
2021-06-29 |
Incyte Corporation |
Aminopyrazine derivatives as PI3K-γ inhibitors
|
SG11202013216RA
(en)
|
2018-07-05 |
2021-01-28 |
Incyte Corp |
Fused pyrazine derivatives as a2a / a2b inhibitors
|
US10875872B2
(en)
|
2018-07-31 |
2020-12-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
US11008344B2
(en)
|
2018-07-31 |
2021-05-18 |
Incyte Corporation |
Tricyclic heteroaryl compounds as STING activators
|
BR112021004094A2
(pt)
|
2018-09-05 |
2021-05-25 |
Incyte Corporation |
formas cristalinas de um inibidor de fosfoinositídeo 3-quinase (pi3k)
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
US11396502B2
(en)
|
2018-11-13 |
2022-07-26 |
Incyte Corporation |
Substituted heterocyclic derivatives as PI3K inhibitors
|
US11161838B2
(en)
|
2018-11-13 |
2021-11-02 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
WO2020102198A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
US20220056049A1
(en)
|
2019-01-07 |
2022-02-24 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
|
SG11202108702XA
(en)
|
2019-02-15 |
2021-09-29 |
Incyte Corp |
Cyclin-dependent kinase 2 biomarkers and uses thereof
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
AU2020290995A1
(en)
|
2019-06-10 |
2022-04-07 |
Incyte Corporation |
Topical treatment of vitiligo by a JAK inhibitor
|
TW202115056A
(zh)
|
2019-06-28 |
2021-04-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
AU2020319875A1
(en)
|
2019-08-01 |
2022-02-17 |
Incyte Corporation |
A dosing regimen for an IDO inhibitor
|
KR20220064369A
(ko)
|
2019-08-14 |
2022-05-18 |
인사이트 코포레이션 |
Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물
|
US20210061809A1
(en)
|
2019-08-26 |
2021-03-04 |
Incyte Corporation |
Triazolopyrimidines as a2a / a2b inhibitors
|
CR20220170A
(es)
|
2019-10-11 |
2022-10-10 |
Incyte Corp |
Aminas bicíclicas como inhibidoras de la cdk2
|
JP2022552324A
(ja)
|
2019-10-14 |
2022-12-15 |
インサイト・コーポレイション |
Fgfr阻害剤としての二環式複素環
|
WO2021076124A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
US11897891B2
(en)
|
2019-12-04 |
2024-02-13 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
KR20230017165A
(ko)
|
2020-03-06 |
2023-02-03 |
인사이트 코포레이션 |
Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법
|
IL297165A
(en)
|
2020-04-16 |
2022-12-01 |
Incyte Corp |
Soysag tricyclic CRS inhibitors
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
AR122505A1
(es)
|
2020-06-02 |
2022-09-14 |
Incyte Corp |
Procesos para preparar un inhibidor de jak1
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
WO2022061351A1
(en)
|
2020-09-16 |
2022-03-24 |
Incyte Corporation |
Topical treatment of vitiligo
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
CA3224674A1
(en)
|
2021-07-07 |
2023-01-12 |
Pei Gan |
Tricyclic compounds as inhibitors of kras
|
CA3224841A1
(en)
|
2021-07-14 |
2023-01-19 |
Zhenwu Li |
Tricyclic compounds as inhibitors of kras
|
US20230174555A1
(en)
|
2021-08-31 |
2023-06-08 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
US20230143938A1
(en)
|
2021-10-01 |
2023-05-11 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
US11939328B2
(en)
|
2021-10-14 |
2024-03-26 |
Incyte Corporation |
Quinoline compounds as inhibitors of KRAS
|
WO2023091746A1
(en)
|
2021-11-22 |
2023-05-25 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
US20230203010A1
(en)
|
2021-12-03 |
2023-06-29 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
US20230183251A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
AR128043A1
(es)
|
2021-12-22 |
2024-03-20 |
Incyte Corp |
Sales y formas sólidas de un inhibidor de fgfr y procesos para su preparación
|
WO2023116884A1
(en)
|
2021-12-24 |
2023-06-29 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
WO2023172921A1
(en)
|
2022-03-07 |
2023-09-14 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
US20240101531A1
(en)
*
|
2022-06-08 |
2024-03-28 |
Xenon Pharmaceuticals Inc. |
Pyridinamine derivatives and their use as potassium channel modulators
|
WO2023245053A1
(en)
|
2022-06-14 |
2023-12-21 |
Incyte Corporation |
Solid forms of a jak inhibitor and process of preparing the same
|
WO2023250430A1
(en)
|
2022-06-22 |
2023-12-28 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
US20240058343A1
(en)
|
2022-08-05 |
2024-02-22 |
Incyte Corporation |
Treatment of urticaria using jak inhibitors
|